Mastercard today announced that its Board of Directors has declared a quarterly cash dividend of 66 cents per share. The cash dividend will be paid on May 9, 2024 to holders of record of its Class A common stock and Class B common stock as of April 9, 2024.The 3M Board of Directors today declared a dividend on the company's common stock of $1.51 per share for the first quarter of 2024. The dividend is payable March 12, 2024, to shareholders of record at the close of business on Feb. 16, 2024. 3M has paid di ...

Gilead Sciences, Inc. (GILD) reported mixed results in the fourth quarter as earnings missed expectations while sales surpassed the same.GILD’s fourth-quarter adjusted earnings of $1.72 per share missed the Zacks Consensus Estimate of $1.76 but increased from $1.67 in the year-ago quarter. The year-over-year increase was due to lower total costs and expenses.Total revenues of $7.1 billion beat the Zacks Consensus Estimate of $7 billion on better-than-expected Veklury (remdesivir) sales, due to an uptick in ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2023 Earnings Call Transcript February 6, 2024 5:00 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O’Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Tyler Van Buren - TD Cowen Salveen Richter - Goldman Sachs Leon Wang - Barclays Terrence Fl ...

For the quarter ended December 2023, Gilead Sciences (GILD) reported revenue of $7.12 billion, down 3.7% over the same period last year. EPS came in at $1.72, compared to $1.67 in the year-ago quarter.The reported revenue represents a surprise of +0.51% over the Zacks Consensus Estimate of $7.08 billion. With the consensus EPS estimate being $1.76, the EPS surprise was -2.27%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...

Financial Performance - FY23 Total Product Sales excluding Veklury increased by 7% YoY to $24.7 billion, driven by HIV and Oncology[7] - Oncology product sales increased by 37% YoY to $2.9 billion, driven by Trodelvy and Cell Therapy[7, 14] - Total HIV sales increased by 6% YoY, contributing approximately $1 billion in FY23 sales growth, with Biktarvy sales up by 14% YoY[7] - Q423 Total Product Sales excluding Veklury were flat YoY and QoQ[7] - FY23 Veklury sales reached $2.2 billion[30] HIV Franchise - HIV sales growth was primarily driven by demand, accounting for approximately 50% of sales growth[21] - Gilead's HIV treatment market share is approximately 48% in the U S[26] - Descovy for PrEP maintains over 40% U S market share despite new regimens and generics[26] Oncology Program - Trodelvy sales in Q423 were $299 million, representing a 53% YoY growth and 5% QoQ growth[35] - Cell Therapy sales in Q423 were $466 million, representing an 11% YoY growth but a 4% QoQ decline[19, 37] Pipeline Updates - EVOKE-01 trial (2L+ mNSCLC) missed the primary endpoint, but showed numerical OS improvement favoring Trodelvy in certain subgroups[7, 40] - OAKTREE trial for obeldesivir in COVID-19 standard-risk population missed the primary endpoint[7, 43] 2024 Guidance - FY24 Total Product Sales are projected to be between $27.1 billion and $27.5 billion[72] - FY24 Product Sales excluding Veklury are expected to grow by 4-6% YoY, reaching $25.8 billion - $26.2 billion[73] - FY24 HIV sales are expected to grow by approximately 4% YoY[73]

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future dividends will be subject to Board approval. About Gilead Scie ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023. “This was another strong year of revenue growth for Gilead’s base business, driven by both HIV and Oncology,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “The strength of the business provides a solid foundation as we enter a new catalyst-rich phase for the company. We are expecting several milestones in 2024, including updat ...

Gilead Sciences Inc. (GILD) is set to report fourth-quarter 2023 results on Feb 6, after market close.The company has a mixed track record, with earnings beating estimates in two of the last four quarters and missing in the remaining two, the average negative surprise being 0.24%. In the last reported quarter, the company posted an earnings surprise of 19.9%.Factors to NoteRevenues in the fourth quarter have likely been boosted by growth in oncology and HIV franchise sales. However, a decline in Veklury (re ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors. Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics. Previously, he was the President and Chief Executive Officer of Global Blood Therapeutics, Inc. where he led the company from a pre-clinical startup to a global c ...

Analysts on Wall Street project that Gilead Sciences (GILD) will announce quarterly earnings of $1.76 per share in its forthcoming report, representing an increase of 5.4% year over year. Revenues are projected to reach $7.08 billion, declining 4.2% from the same quarter last year.The consensus EPS estimate for the quarter has undergone a downward revision of 1.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estim ...